The primary endpoint was seroconversion rate 2 weeks post second dose100% of PLWH with CD4+ T cell counts >300 seroconverted following vaccination96% of PLWH with CD4+ T cell counts <300PLWH were the only secondary immunodeficiency group that did not have a higher likelihood to seroconvert. This evidence concerns the gene CD4 and immunodeficiency disease.